GenScript Biotech Corporation and Tamarind Bio have announced a strategic partnership to establish a unified validation engine that seamlessly bridges AI-powered molecular design with wet-lab experimental testing. By directly integrating Tamarind Bio’s platform which provides researchers access to over 300 computational biology models with GenScript’s end-to-end laboratory infrastructure, the collaboration allows scientists to submit AI-generated biological sequences directly for synthesis, expression, and testing without leaving the connected workflow. This automated integration addresses a growing bottleneck in AI-driven life sciences by drastically reducing manual handoffs and enabling researchers to generate model-ready experimental data in as little as four days. Contextualizing the necessity of real-world biological verification alongside computational modeling, “AI is opening doors the industry could only imagine a few years ago,” said Ray Chen, President of GenScript Life Science Group.
Also Read: Revvity Launches “Signals for Startups” to Empower Early-Stage Biotechs
“But biology still determines what moves forward. By connecting AI-powered design to experimental proof, this partnership is helping lay the groundwork for the next generation of scientific innovation.” Underscoring the goal of democratizing computational biology and accelerating R&D timelines, “Tamarind was built to make advanced molecular design accessible to every scientist,” said Deniz Kavi, CEO and Co-Founder of Tamarind Bio. “Partnering with GenScript bridges the gap between digital design and physical experimentation, empowering scientists to turn promising candidates into actionable lab results faster than ever.” Ultimately, this connected framework empowers research teams across therapeutics and industrial biotechnology to evaluate candidate molecules faster, build higher-quality datasets, and make better-informed discovery decisions.